Compare MXC & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | HCWB |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 14.8M |
| IPO Year | 1995 | 2021 |
| Metric | MXC | HCWB |
|---|---|---|
| Price | $7.51 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 8.5K | ★ 660.7K |
| Earning Date | 02-10-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.63 | 0.37 |
| Revenue | $2,705,235.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.92 | ★ $11.62 |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $7.16 | $0.25 |
| 52 Week High | $16.48 | $7.35 |
| Indicator | MXC | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 73.44 |
| Support Level | N/A | $3.66 |
| Resistance Level | $9.56 | $4.88 |
| Average True Range (ATR) | 0.46 | 0.25 |
| MACD | 0.02 | 0.37 |
| Stochastic Oscillator | 46.41 | 72.42 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.